Framework of clonal mutations concurrent with WT1 mutations in adults with acute myeloid leukemia: Alliance for Clinical Trials in Oncology study

Bhavana Bhatnagar; Jessica Kohlschmidt; Shelley J. Orwick; Daelynn R. Buelow; Sydney Fobare; Christopher C. Oakes; Jonathan E. Kolitz; Geoff Uy; Wendy Stock; Bayard L. Powell; Deedra Nicolet; Erin K. Hertlein; Krzysztof Mrózek; James S. Blachly; Ann Kathrin Eisfeld; Sharyn D. Baker; John C. Byrd

doi:10.1182/bloodadvances.2023010482

Framework of clonal mutations concurrent with WT1 mutations in adults with acute myeloid leukemia: Alliance for Clinical Trials in Oncology study

Bhavana Bhatnagar, Jessica Kohlschmidt, Shelley J. Orwick, Daelynn R. Buelow, Sydney Fobare, Christopher C. Oakes, Jonathan E. Kolitz, Geoff Uy, Wendy Stock, Bayard L. Powell, Deedra Nicolet, Erin K. Hertlein, Krzysztof Mrózek, James S. Blachly, Ann Kathrin Eisfeld, Sharyn D. Baker, John C. Byrd

Research output: Contribution to journal › Letter › peer-review

2 Scopus citations

Original language	English
Pages (from-to)	4671-4675
Number of pages	5
Journal	Blood Advances
Volume	7
Issue number	16
DOIs	https://doi.org/10.1182/bloodadvances.2023010482
State	Published - Aug 16 2023

Access to Document

10.1182/bloodadvances.2023010482

Cite this

Bhatnagar, B., Kohlschmidt, J., Orwick, S. J., Buelow, D. R., Fobare, S., Oakes, C. C., Kolitz, J. E., Uy, G., Stock, W., Powell, B. L., Nicolet, D., Hertlein, E. K., Mrózek, K., Blachly, J. S., Eisfeld, A. K., Baker, S. D., & Byrd, J. C. (2023). Framework of clonal mutations concurrent with WT1 mutations in adults with acute myeloid leukemia: Alliance for Clinical Trials in Oncology study. Blood Advances, 7(16), 4671-4675. https://doi.org/10.1182/bloodadvances.2023010482

@article{8c25435705bd4bea8a708e50c6cd8967,

title = "Framework of clonal mutations concurrent with WT1 mutations in adults with acute myeloid leukemia: Alliance for Clinical Trials in Oncology study",

author = "Bhavana Bhatnagar and Jessica Kohlschmidt and Orwick, {Shelley J.} and Buelow, {Daelynn R.} and Sydney Fobare and Oakes, {Christopher C.} and Kolitz, {Jonathan E.} and Geoff Uy and Wendy Stock and Powell, {Bayard L.} and Deedra Nicolet and Hertlein, {Erin K.} and Krzysztof Mr{\'o}zek and Blachly, {James S.} and Eisfeld, {Ann Kathrin} and Baker, {Sharyn D.} and Byrd, {John C.}",

note = "Funding Information: Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under award numbers U10CA180821, U10CA180882, and U24CA196171, (to the Alliance for Clinical Trials in Oncology), UG1CA189824, UG1CA233327, UG1CA233331, UG1CA233338, UG1CA233339, P30CA016058, and R35 CA198183 (J.C.B.), the Four Winds Foundation, Harry F. Mangurian Foundation, the Coleman Leukemia Research Foundation (J.C.B.), and The Ohio State University Comprehensive Cancer Center Pelotonia Foundation (A.-K.E., J.S.B., S.D.B., and J.C.B.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health (https://acknowledgments.alliancefound.org). Funding Information: Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under award numbers U10CA180821, U10CA180882, and U24CA196171, (to the Alliance for Clinical Trials in Oncology), UG1CA189824, UG1CA233327, UG1CA233331, UG1CA233338, UG1CA233339, P30CA016058, and R35 CA198183 (J.C.B.), the Four Winds Foundation, Harry F. Man-gurian Foundation, the Coleman Leukemia Research Foundation (J.C.B.), and The Ohio State University Comprehensive Cancer Center Pelotonia Foundation (A.-K.E., J.S.B., S.D.B., and J.C.B.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health (https://acknowledgments.alliancefound.org).",

year = "2023",

month = aug,

day = "16",

doi = "10.1182/bloodadvances.2023010482",

language = "English",

volume = "7",

pages = "4671--4675",

journal = "Blood Advances",

issn = "2473-9529",

number = "16",

}

Bhatnagar, B, Kohlschmidt, J, Orwick, SJ, Buelow, DR, Fobare, S, Oakes, CC, Kolitz, JE, Uy, G, Stock, W, Powell, BL, Nicolet, D, Hertlein, EK, Mrózek, K, Blachly, JS, Eisfeld, AK, Baker, SD & Byrd, JC 2023, 'Framework of clonal mutations concurrent with WT1 mutations in adults with acute myeloid leukemia: Alliance for Clinical Trials in Oncology study', Blood Advances, vol. 7, no. 16, pp. 4671-4675. https://doi.org/10.1182/bloodadvances.2023010482

TY - JOUR

T1 - Framework of clonal mutations concurrent with WT1 mutations in adults with acute myeloid leukemia

T2 - Alliance for Clinical Trials in Oncology study

AU - Bhatnagar, Bhavana

AU - Kohlschmidt, Jessica

AU - Orwick, Shelley J.

AU - Buelow, Daelynn R.

AU - Fobare, Sydney

AU - Oakes, Christopher C.

AU - Kolitz, Jonathan E.

AU - Uy, Geoff

AU - Stock, Wendy

AU - Powell, Bayard L.

AU - Nicolet, Deedra

AU - Hertlein, Erin K.

AU - Mrózek, Krzysztof

AU - Blachly, James S.

AU - Eisfeld, Ann Kathrin

AU - Baker, Sharyn D.

AU - Byrd, John C.

N1 - Funding Information: Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under award numbers U10CA180821, U10CA180882, and U24CA196171, (to the Alliance for Clinical Trials in Oncology), UG1CA189824, UG1CA233327, UG1CA233331, UG1CA233338, UG1CA233339, P30CA016058, and R35 CA198183 (J.C.B.), the Four Winds Foundation, Harry F. Mangurian Foundation, the Coleman Leukemia Research Foundation (J.C.B.), and The Ohio State University Comprehensive Cancer Center Pelotonia Foundation (A.-K.E., J.S.B., S.D.B., and J.C.B.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health (https://acknowledgments.alliancefound.org). Funding Information: Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under award numbers U10CA180821, U10CA180882, and U24CA196171, (to the Alliance for Clinical Trials in Oncology), UG1CA189824, UG1CA233327, UG1CA233331, UG1CA233338, UG1CA233339, P30CA016058, and R35 CA198183 (J.C.B.), the Four Winds Foundation, Harry F. Man-gurian Foundation, the Coleman Leukemia Research Foundation (J.C.B.), and The Ohio State University Comprehensive Cancer Center Pelotonia Foundation (A.-K.E., J.S.B., S.D.B., and J.C.B.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health (https://acknowledgments.alliancefound.org).

PY - 2023/8/16

Y1 - 2023/8/16

UR - http://www.scopus.com/inward/record.url?scp=85169818895&partnerID=8YFLogxK

U2 - 10.1182/bloodadvances.2023010482

DO - 10.1182/bloodadvances.2023010482

M3 - Letter

C2 - 37289505

AN - SCOPUS:85169818895

SN - 2473-9529

VL - 7

SP - 4671

EP - 4675

JO - Blood Advances

JF - Blood Advances

IS - 16

ER -

Framework of clonal mutations concurrent with WT1 mutations in adults with acute myeloid leukemia: Alliance for Clinical Trials in Oncology study

Access to Document

Other files and links

Cite this